Moleculin Biotech Inc (MBRX.OQ)
MBRX.OQ on NASDAQ Stock Exchange Capital Market
0.80USD
25 Sep 2020
0.80USD
25 Sep 2020
Change (% chg)
-- (--)
-- (--)
Prev Close
$0.80
$0.80
Open
--
--
Day's High
--
--
Day's Low
--
--
Volume
--
--
Avg. Vol
337,149
337,149
52-wk High
$1.97
$1.97
52-wk Low
$0.32
$0.32
Revenue & Earnings Per Share
| Revenue* | Earnings Per Share** | ||
|---|---|---|---|
| FY 2020 | Jun '20 | 0.00 | -0.170 |
| Mar '20 | 0.00 | -0.024 | |
| FY 2019 | Dec '19 | 0.00 | -0.083 |
| Sep '19 | 0.00 | -0.091 | |
| Jun '19 | 0.00 | -0.029 | |
| Mar '19 | 0.00 | -0.139 | |
| FY 2018 | Dec '18 | 0.00 | -0.101 |
| Sep '18 | 0.00 | -0.076 | |
| Jun '18 | 0.00 | -0.198 | |
| Mar '18 | 0.00 | -0.083 |
*Note: Units in Millions ofU.S. Dollars
**Note: Units in U.S. Dollars
Consensus Estimates Analysis
| # of Estimates | Mean | High | Low | 1 Year Ago | |
|---|---|---|---|---|---|
| SALES (in millions) | |||||
| Quarter Ending Sep-20 | 2 | 0.00 | 0.00 | 0.00 | -- |
| Quarter Ending Dec-20 | 2 | 0.00 | 0.00 | 0.00 | -- |
| Year Ending Dec-20 | 2 | 0.00 | 0.00 | 0.00 | 0.00 |
| Year Ending Dec-21 | 2 | 0.00 | 0.00 | 0.00 | 0.00 |
| Earnings (per share) | |||||
| Quarter Ending Sep-20 | 3 | -0.09 | -0.09 | -0.10 | -- |
| Quarter Ending Dec-20 | 3 | -0.10 | -0.09 | -0.12 | -- |
| Year Ending Dec-20 | 3 | -0.40 | -0.38 | -0.43 | -0.41 |
| Year Ending Dec-21 | 3 | -0.38 | -0.34 | -0.42 | -0.41 |
Sales and Profit Figures in US Dollar (USD);
Valuation Ratios
| Company | industry | sector | ||
|---|---|---|---|---|
| P/E Ratio (TTM) | -- | 33.92 | 43.05 | |
| P/E High - Last 5 Yrs. | -- | 43.73 | 47.04 | |
| P/E Low - Last 5 Yrs. | -- | 25.29 | 25.37 | |
| Beta | 2.11 | 0.87 | 0.86 | |
| Price to Sales (TTM) | -- | 4.37 | 10.01 | |
| Price to Book (MRQ) | 3.11 | 4.12 | 4.50 | |
| Price to Tangible Book (MRQ) | 11.07 | 4.86 | 6.11 | |
| Price to Cash Flow (TTM) | -- | 21.44 | 31.20 | |
| % Owned Institutions | -- | 0.00 | 0.00 | |
Dividends
| Company | industry | sector | ||
|---|---|---|---|---|
| Dividend Yield | -- | 1.53 | 1.42 | |
| Dividend Yield - 5 Year Avg | -- | 1.63 | 1.52 | |
| Dividend 5 Year Growth Rate | -- | 4.39 | 5.13 | |
| Payout Ratio(TTM) | -- | 50.85 | 47.87 | |
Growth Rates
| Company | industry | sector | ||
|---|---|---|---|---|
| Sales (MRQ) vs Qtr. 1 Yr. Ago | -- | 1.36 | 0.86 | |
| Sales (TTM) vs TTM 1 Yr. Ago | -- | 7.73 | 7.50 | |
| Sales - 5 Yr. Growth Rate | -- | 5.88 | 6.15 | |
| EPS (MRQ) vs Qtr. 1 Yr. Ago | -490.28 | 82.35 | 69.32 | |
| EPS (TTM) vs TTM 1 Yr. Ago | -6.76 | -- | -- | |
| EPS - 5 Yr. Growth Rate | -- | 8.56 | 8.76 | |
| Capital Spending - 5 Yr. Growth Rate | -- | 12.96 | 12.85 | |
Financial Strength
| Company | industry | sector | |
|---|---|---|---|
| Quick Ratio (MRQ) | -- | 2.30 | 2.36 |
| Current Ratio (MRQ) | 5.28 | 3.13 | 3.19 |
| LT Debt to Equity (MRQ) | 0.00 | 12.60 | 14.54 |
| Total Debt to Equity (MRQ) | 0.00 | 18.28 | 20.40 |
| Interest Coverage (TTM) | -- | 12.41 | 15.02 |
Profitability Ratios
| Company | industry | sector | ||
|---|---|---|---|---|
| Gross Margin (TTM) | -- | 54.83 | 54.45 | |
| Gross Margin - 5 Yr. Avg. | -- | 54.74 | 54.29 | |
| EBITD Margin (TTM) | -- | -- | -- | |
| EBITD - 5 Yr. Avg | -- | 18.98 | 11.89 | |
| Operating Margin (TTM) | -- | 15.55 | -6.22 | |
| Operating Margin - 5 Yr. Avg. | -- | 14.60 | 6.88 | |
| Pre-Tax Margin (TTM) | -- | 15.93 | -7.94 | |
| Pre-Tax Margin - 5 Yr. Avg. | -- | 14.89 | 7.07 | |
| Net Profit Margin (TTM) | -- | 12.25 | -11.55 | |
| Net Profit Margin - 5 Yr. Avg. | -- | 11.23 | 3.51 | |
| Effective Tax Rate (TTM) | -- | 16.99 | 17.91 | |
| Effective Tax Rate - 5 Yr. Avg. | -- | 22.15 | 22.24 | |
Efficiency
| Company | industry | sector | ||
|---|---|---|---|---|
| Revenue/Employee (TTM) | 0 | 974,369,744 | 840,174,798 | |
| Net Income/Employee (TTM) | -1,751,182 | 111,791,358 | 96,273,138 | |
| Receivable Turnover (TTM) | -- | 5.46 | 5.44 | |
| Inventory Turnover (TTM) | -- | 2.53 | 3.44 | |
| Asset Turnover (TTM) | 0.00 | 0.81 | 0.78 | |
Management Effectiveness
| Company | industry | sector | ||
|---|---|---|---|---|
| Return on Assets (TTM) | -60.93 | 10.40 | 9.85 | |
| Return on Assets - 5 Yr. Avg. | -57.20 | 11.07 | 10.61 | |
| Return on Investment (TTM) | -77.20 | 12.97 | 12.33 | |
| Return on Investment - 5 Yr. Avg. | -67.91 | 13.85 | 13.28 | |
| Return on Equity (TTM) | -102.13 | 14.67 | 14.28 | |
| Return on Equity - 5 Yr. Avg. | -83.63 | 16.52 | 15.88 | |
| 1 Year | 3 Year | 5 Year | |
|---|---|---|---|
| Sales % | -- | -- | -- |
| EPS (TTM) % | 29.27 | -- | -- |
| Dividend % | -- | -- | -- |
Note: Units in Millions of US Dollars
Performance for Moleculin Biotech Inc
| Period | % Actual |
% vs. S&P 500 |
Rank In Industry |
Industry Rank |
|---|---|---|---|---|
| 4 Week | -9.67 | -3.93 | 53 | 54 |
| 13 Week | -16.28 | -23.63 | 47 | 42 |
| 26 Week | 27.67 | -1.63 | 99 | 74 |
| 52 Week | -29.50 | -36.36 | 51 | 66 |
| YTD | -12.17 | -13.98 | 66 | 68 |
Note:: Rank is a percentile that ranges from 0 to 99, with 99 = best.
- BRIEF-Moleculin Provides Update On Annamycin Clinical Development
- BRIEF-Moleculin Announces Preclinical Data Confirms Efficacy Of Annamycin In Lung Metastases
- BRIEF-Moleculin Announces Confirmatory In Vitro Analysis Of WP1122
- BRIEF-Moleculin Reports Submission To Expand Clinical Sites In European AML Trial
- BRIEF-Moleculin Announces Common Stock Will Resume Trading On The Nasdaq On May 28
Institutional Holders
| % Shares Owned: | 18.61% |
| # of Holders: | 34 |
| Total Shares Held: | 11,482,195 |
| 3 Mo. Net Change: | -916,697 |
| # New Positions: | 14 |
| # Closed Positions: | 6 |
| # Increased Positions: | 19 |
| # Reduced Positions: | 9 |
| # Net Buyers: | 10 |
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.